Investigational drug · Phase 3
PBO
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Primary Generalized Epilepsy, Treatment Resistant Depression.
Phase 3Last checked: Nov 19, 2026Latest source record: Jul 2, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
0 still active
All registered trials
271
Any phase or sponsor naming "PBO"
First trial start
2018
Oct 3, 2018
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "PBO", any sponsor or status.
Conditions studied
As listed on its trial records.
- Primary Generalized Epilepsy
- Treatment Resistant Depression
Approved drugs for the same conditions: Epilepsy and seizures · Depression (major depressive disorder) · Neurology · Psychiatry
Largest trials
Live from ClinicalTrials.gov: studies naming "PBO" as an intervention, largest first.
- Mass Drug Administration of Dihydroartemisinin-piperaquine + Single Low-dose Primaquine to Accelerate Toward Elimination ActivitiesPivotal-lookingCompleted
University of California, San FranciscoAcademic, hospital or other
NCT04864444 · 10,715 participants · Start Jun 19, 2021 · Primary completion Dec 31, 2022
Drug: Dihydroartemisinin-piperaquine; Primaquine · For: Malaria,Falciparum; Malaria
Sites: Tambacounda, Senegal
- Cardiovascular Outcomes Study of Naltrexone SR/Bupropion SR in Overweight and Obese Subjects With Cardiovascular Risk Factors (The Light Study)Pivotal-lookingTerminated
Orexigen Therapeutics, IncIndustry
NCT01601704 · 8,910 participants · Start Jun 2012 · Primary completion Aug 2015
Drug: NB32; PBO · For: Obesity; Overweight
Sites: Birmingham, Alabama; Dothan, Alabama; Mobile, Alabama · 224 sites in all
- A Trial to Compare the Efficacy, Safety and Tolerability of Combinations of 3 Anti-malarial Drugs Against Combina-tions of 2 Anti-malarial Drugs.Pivotal-lookingCompleted
University of OxfordAcademic, hospital or other
NCT03923725 · 2,583 participants · Start Sep 1, 2020 · Primary completion Mar 15, 2024
Drug: Artemether-lumefantrine+ Amodiaquine (AL+AQ); Artemether-lumefantrine + placebo (AL+PBO) and 2 more · For: Plasmodium Falciparum Malaria (Uncomplicated)
Sites: Bobo-Dioulasso, Burkina Faso; Kinshasa, Democratic Republic of the Congo; Conakry, Guinea · 8 sites in all
- A Two Year Safety and Efficacy Study in Obese Patients (0364-015)(TERMINATED)Pivotal-lookingTerminated
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT00131404 · 2,400 participants · Start Sep 2005 · Primary completion Feb 2007
Drug: taranabant; Comparator: Placebo · For: Obesity
- A Study of MK0364 in Obese Patients (0364-014)Pivotal-lookingTerminated
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT00131391 · 2,400 participants · Start Jul 2005 · Primary completion Feb 2008
Drug: Comparator: taranabant; Comparator: placebo · For: Obesity
- LDL-C Assessment With PCSK9 Monoclonal Antibody Inhibition Combined With Statin Therapy-2Pivotal-lookingCompleted
AmgenAmgen (AMGN)
NCT01763866 · 2,067 participants · Start Jan 15, 2013 · Primary completion Nov 12, 2013
Drug: Evolocumab; Ezetimibe and 5 more · For: Hyperlipidemia
Sites: Birmingham, Alabama; Glendale, Arizona; Tucson, Arizona · 244 sites in all
- Intermittent and Daily Dosing for Episodic (Periodic) Asthma (0476-302)(COMPLETED)Pivotal-lookingCompleted
Organon and CoIndustry
NCT00337675 · 1,771 participants · Start Oct 2006 · Primary completion Aug 2009
Drug: montelukast sodium; Comparator: Placebo (unspecified) and 1 more · For: Asthma
- A Study of Immune System Proteins in Participants With Mild to Moderate COVID-19 IllnessPivotal-lookingCompleted
Eli Lilly and CompanyEli Lilly (LLY)
NCT04634409 · 1,755 participants · Start Oct 29, 2020 · Primary completion Jul 27, 2021
Drug: Bamlanivimab; Etesevimab and 3 more · For: COVID-19
Sites: Birmingham, Alabama; Mesa, Arizona; Scottsdale, Arizona · 141 sites in all
Michigan State UniversityAcademic, hospital or other
NCT04327440 · 1,691 participants · Start Feb 4, 2020 · Primary completion Jun 30, 2021
Drug: RTS,S/AS01 malaria vaccine · For: Malaria, Malaria Vaccine, Insecticide-treated Bednets
Sites: Blantyre, Malawi
- Montelukast Asthmatic Smoker Study (0476-332)(COMPLETED)Pivotal-lookingCompleted
Organon and CoIndustry
NCT00284856 · 1,640 participants · Start May 2006 · Primary completion Apr 2010
Drug: montelukast sodium; Comparator: Placebo and 2 more · For: Asthma
Newest research
PubMed records naming it or its code names, newest first.
- Pyrethroid resistance intensity and mechanisms in Anopheles gambiae sensu lato (Diptera: Culicidae) from Oyo State, Nigeria.
Ibrahim KT, Braimah JA, Oyebamiji DA, et al. · Parasitol Int 2027
- Enhanced gamma-ray shielding performance of SrO-containing borate-based glasses doped with PbO and Eu2O3 featuring tunable optical properties.
Sayyed MI, Biradar S, Mahmoud KA · Appl Radiat Isot 2026
- Physical,Phy-X/PSD based radiation shielding and electrical properties of Dy2O3ߜdoped ZrO2ߜPbOߜAs2O3Glass system.
Chitti Babu A, Naresh P, Venkata Narmada T, et al. · Appl Radiat Isot 2026
- Inside membranes: unveiling chain conformation in poly(butylene oxide)-block-polyglycidol polymersomes.
Yu Y, Du H, Mondo GB, et al. · J Colloid Interface Sci 2026
- Indoor residual spraying of distinct insecticide formulations in a household-scale micro-mosaic format: Feasibility and effectiveness for malaria vector control in rural Zambia.
Chinula D, Mumba K, Zulu R, et al. · Med Vet Entomol 2026
- Effect of lemborexant on insomnia severity, morning alertness, and cognition in participants with insomnia disorder and mild obstructive sleep apnea.
Gottschalk R, Lowe A, Cheng JY, et al. · Sleep Med X 2026
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.